Search

… Last updated 2021-11-09 Summary Product Janssen and Vaxzevria (AstraZeneca) COVID-19 vaccines Issue Health products - … following symptoms after vaccination with the Janssen and Vaxzevria COVID-19 vaccines: unexplained bleeding, …

… (CLS) have been reported following vaccination with AstraZeneca COVID-19 Vaccine. A history of CLS was noted in … affected AstraZeneca COVID-19 Vaccine, COVID-19 Vaccine (ChAdOx1-S [recombinant]) 5 mL solution for intramuscular … AstraZeneca Canada Inc. COVISHIELD, COVID-19 Vaccine (ChAdOx1-S [recombinant]) 5 mL solution for intramuscular …

… been observed very rarely following vaccination with the AstraZeneca COVID-19 Vaccine. Health Canada has assessed the … affected AstraZeneca COVID-19 Vaccine, COVID-19 Vaccine (ChAdOx1-S [recombinant]) 5 mL solution for intramuscular … AstraZeneca Canada Inc. COVISHIELD, COVID-19 Vaccine (ChAdOx1-S [recombinant]) 5 mL solution for intramuscular …

… COVISHIELD (manufactured by Serum Institute of India) and AstraZeneca COVID-19 VACCINE (manufactured by AstraZeneca) are ChAdOx1-S recombinant vaccines developed by AstraZeneca and … section). Products affected COVISHIELD, COVID-19 Vaccine (ChAdOx1-S [recombinant]) 5 mL solution for intramuscular …

… information during the initial distribution of the AstraZeneca COVID-19 Vaccine. Audiences Healthcare … and healthcare professionals at identified points of use. AstraZeneca Canada Inc. (AstraZeneca) (the Canadian importer … affected AstraZeneca COVID-19 Vaccine, COVID-19 Vaccine (ChAdOx1-S [recombinant]), 5 mL solution for intramuscular …

… information during the initial distribution of the AstraZeneca COVID-19 Vaccine (US-labelled vaccine supplies) … and healthcare professionals at identified points of use. AstraZeneca Canada Inc. (AstraZeneca) (the Canadian importer … and Supplier in Canada AstraZeneca COVID-19 Vaccine, (ChAdOx1-S [recombinant]) Suspension for Intramuscular …

… number: RA-75389 Last updated: 2021-06-29 Summary Product: AstraZeneca and COVISHIELD COVID-19 vaccines Issue: Health … is updating the product monograph—or label—for the AstraZeneca and COVISHIELD COVID-19 vaccines to add capillary … with a history of capillary leak syndrome to not get the AstraZeneca or COVISHIELD COVID-19 vaccine. The label has …

… adverse events in Europe following immunization with the AstraZeneca COVID-19 vaccine, and would like to reassure … these events. To date, no adverse events related to the AstraZeneca COVID-19 vaccine, or the version manufactured by … temporarily paused the use of specific batches of the AstraZeneca vaccine or use of the AstraZeneca vaccine …

… RA-19000556 This is duplicated text of a letter from AstraZeneca Canada Inc . Contact the company for a copy of … failed to prolong survival and increased bleeding events. AstraZeneca Canada Inc., in consultation with Health Canada, … Registry program, Health Canada, in collaboration with AstraZeneca, has requested that you be made aware of these …

… RA-17000265 This is duplicated text of a letter from AstraZeneca. Contact the company for a copy of any … is estimated to be more than 1.5 million patient years. AstraZeneca Canada Inc. would like to update you on important … if you experience any of the above signs and symptoms." AstraZeneca Canada Inc. continues to work closely with Health …

… RA-19000311 This is duplicated text of a letter from AstraZeneca Canada Inc. Contact the company for a copy of any … Safety Information on IRESSA (gefitinib) 250 mg Tablets AstraZeneca Canada Inc. 1004 Middlegate Road Mississauga … 250 mg tablets Health Canada, in consultation with AstraZeneca Canada Inc., is recommending new restrictions on …

… RA-17000985 This is duplicated text of a letter from AstraZeneca Canada Inc .Contact the company for a copy of any … CRESTOR ® (rosuvastatin) Dear Health Care Professional, AstraZeneca Canada Inc., in consultation with Health Canada, … available in Canada since February 2003. In June 2004 , AstraZeneca Canada Inc., in consultation with Health Canada, …

… RA-170001140 This is duplicated text of a letter from AstraZeneca Canada Inc. Contact the company for a copy of any … long-acting beta agonists Dear Health Care Professional, AstraZeneca Canada Inc. in consultation with Health Canada … data for Oxeze ® were not included in the US review and AstraZeneca did not participate in the PADAC meeting. The …

… RA-1900010 This is duplicated text of a letter from AstraZeneca Contact the company for a copy of any references, … Problems for Patients Taking Accolate ® (zafirlukast) AstraZeneca Canada Inc. would like to update you on important … please contact your physician or pharmacist, or contact AstraZeneca Canada Inc. at 1-800-668-6000. Any suspected …

… number: RA-15087 This is duplicated text of a letter from AstraZeneca Canada Inc. Contact the company for a copy of any … 200 µg per metered dose (200 doses; DIN 00851752) AstraZeneca Canada Inc., in consultation with Health Canada, … for oral inhalation, 200 µg per metered dose (200 doses).  AstraZeneca Canada has received a small number of product …